Supplementary Information
AKI, ovarian cancer, CRS, acute kidney injury
OVARIAN CANCER, CAVITY, ADVERSE EFFECTS
The online version contains supplementary material available at 10.1245/s10434-023-14216-6.Open access funding provided by SCELC, Statewide California Electronic Library ConsortiumHyperthermic intraperitoneal chemotherapy (HIPEC) is the delivery of heated chemotherapy (42 °C) into the intraperitoneal (IP) cavity immediately after optimal cytoreductive surgery (CRS). The OVHIPEC-1, randomized, phase III trial evaluated HIPEC with cisplatin 100 mg/mThe incidence of acute kidney injury (AKI) with cisplatin during HIPEC has been reported at 15–31% for cisplatin doses 50–100 mg/mUse of ST versus no ST (nST) has not been prospectively evaluated in ovarian cancer patients undergoing HIPEC with cisplatin. Rather, interim analyses showing higher-than-expected, renal, adverse effects has led to protocol amendment with inclusion of ST prophylaxis in some key HIPEC trials in ovarian cancer.